[{"orgOrder":0,"company":"Ocugen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ocugen to Discontinue Phase 3 oGVHD Trial","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Brimonidine Tartrate","moa":"Adrenergic receptor alpha-2","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Ocugen","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"Ocugen \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ocugen \/ Not Applicable"},{"orgOrder":0,"company":"SENJU PHARMACEUTICAL CO LTD","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Senju Pharmaceutical Launches New Combination Ophthalmic Solution for the Treatment of Glaucoma and Ocular Hypertension","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Brimonidine Tartrate","moa":"Adrenergic receptor alpha-2","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"SENJU PHARMACEUTICAL CO LTD","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Ophthalmic Suspension","sponsorNew":"SENJU PHARMACEUTICAL CO LTD \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"SENJU PHARMACEUTICAL CO LTD \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bausch Health's LUMIFY\u00ae and BESIVANCE\u00ae Eye Drops Preserved With Benzalkonium Chloride Completly Inactivats SARS-CoV-2","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Brimonidine Tartrate","moa":"Adrenergic receptor alpha-2","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Bausch Health","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Eye Drops","sponsorNew":"Bausch Health \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Bausch Health \/ Not Applicable"},{"orgOrder":0,"company":"Visus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Visus Therapeutics Initiates Phase 2 Clinical Trial of BRIMOCHOL for the Treatment of Presbyopia","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Carbachol","moa":"Muscarinic M1 receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Visus Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"Visus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Visus Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Visus Therapeutics","sponsor":"Johnson & Johnson","pharmaFlowCategory":"D","amount":"$36.0 million","upfrontCash":"Undisclosed","newsHeadline":"Visus Therapeutics Announces $36 Million Series A Financing to Advance Development of Novel Presbyopia-Correcting Eye Drop","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Series A Financing","leadProduct":"Carbachol","moa":"Muscarinic M1 receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Visus Therapeutics","amount2":0.040000000000000001,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0.040000000000000001,"dosageForm":"Eye Drop","sponsorNew":"Visus Therapeutics \/ Johnson & Johnson Innovation","highestDevelopmentStatusID":"10","companyTruncated":"Visus Therapeutics \/ Johnson & Johnson Innovation"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Alcon Inc","pharmaFlowCategory":"D","amount":"$355.0 million","upfrontCash":"Undisclosed","newsHeadline":"Alcon to Acquire U.S. Commercialization Rights to Ophthalmic Eye Drop Simbrinza","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Acquisition","leadProduct":"Brinzolamide","moa":"CA2","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0.35999999999999999,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0.35999999999999999,"dosageForm":"Ophthalmic suspension","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Alcon","highestDevelopmentStatusID":"12","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Alcon"},{"orgOrder":0,"company":"Visus Therapeutics","sponsor":"LSP","pharmaFlowCategory":"D","amount":"$20.0 million","upfrontCash":"Undisclosed","newsHeadline":"Visus Secures $20 Million in Additional Financing Led by New Investor LSP","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Financing","leadProduct":"Carbachol","moa":"Muscarinic M1 receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Visus Therapeutics","amount2":0.02,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0.02,"dosageForm":"Eye Drop","sponsorNew":"Visus Therapeutics \/ LSP","highestDevelopmentStatusID":"10","companyTruncated":"Visus Therapeutics \/ LSP"},{"orgOrder":0,"company":"Apotex Fermentation Inc.","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Apotex Corp. Launches First-to-Market Authorized Generic Version of Combigan\u00ae Ophthalmic Solution in the United States","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Brimonidine Tartrate","moa":"Adrenergic receptor alpha-2","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Apotex Fermentation Inc.","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Ophthalmic Suspension","sponsorNew":"Apotex Fermentation Inc. \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Apotex Fermentation Inc. \/ Not Applicable"},{"orgOrder":0,"company":"Visus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Visus Therapeutics Initiates Phase 3 Pivotal Trials of BRIMOCHOL\u2122 PF for the Treatment of Presbyopia","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Carbachol","moa":"Muscarinic M1 receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Visus Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"Visus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Visus Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"LENZ Therapeutics","sponsor":"Ji Xing Pharmaceuticals","pharmaFlowCategory":"D","amount":"$110.0 million","upfrontCash":"$15.0 million","newsHeadline":"LENZ Therapeutics and JIXING Announce an Exclusive Greater China License Agreement; RTW to Invest in LENZ Therapeutics","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Aceclidine Hydrochloride","moa":"Muscarinic receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"LENZ Therapeutics","amount2":0.11,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.11,"dosageForm":"Opthalamic Solution","sponsorNew":"LENZ Therapeutics \/ Ji Xing Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"LENZ Therapeutics \/ Ji Xing Pharmaceuticals"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sandoz Launches Generic Brimonidine Tartrate\/timolol Maleate Eyedrop in Us for Patients With Ocular Hypertension, Expanding Leading Ophthalmic Portfolio","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Brimonidine Tartrate","moa":"Adrenergic receptor alpha-2","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Sandoz B2B","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Sandoz B2B \/ ","highestDevelopmentStatusID":"12","companyTruncated":"Sandoz B2B \/ "},{"orgOrder":0,"company":"Visus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Visus Therapeutics Announces New Scientific Data to Be Presented During the 2022 ARVO Annual Meeting","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Carbachol","moa":"Muscarinic M1 receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Visus Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"Visus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Visus Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Visus Therapeutics","sponsor":"Zhaoke Ophthalmology","pharmaFlowCategory":"D","amount":"$130.0 million","upfrontCash":"$15.0 million","newsHeadline":"Visus Therapeutics, Inc., and Zhaoke Ophthalmology Limited Announce Exclusive Licensing Agreement to Commercialize BRIMOCHOL\u2122 PF and Carbachol PF in Greater China, South Korea and Select Southeast Asian Markets for the Treatment of Presbyopia","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Carbachol","moa":"Muscarinic M1 receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Visus Therapeutics","amount2":0.13,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0.13,"dosageForm":"Inhalation","sponsorNew":"Visus Therapeutics \/ Zhaoke Ophthalmology","highestDevelopmentStatusID":"10","companyTruncated":"Visus Therapeutics \/ Zhaoke Ophthalmology"},{"orgOrder":0,"company":"Slayback Pharma","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Dr. Reddy's Laboratories Enters Into a Licensing Agreement with Slayback Pharma to Obtain Exclusive Rights in The First-To-File ANDA For the Private Label Version of Lumify in The U.S.","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Brimonidine Tartrate","moa":"Adrenergic receptor alpha-2","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Slayback Pharma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution","sponsorNew":"Slayback Pharma \/ Dr. Reddy\u2019s Laboratories","highestDevelopmentStatusID":"10","companyTruncated":"Slayback Pharma \/ Dr. Reddy\u2019s Laboratories"},{"orgOrder":0,"company":"Visiox Pharma","sponsor":"Founding Partners","pharmaFlowCategory":"D","amount":"$7.0 million","upfrontCash":"Undisclosed","newsHeadline":"Visiox Pharma Announces Close of $7M Seed Round","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Financing","leadProduct":"Brimonidine Tartrate","moa":"Adrenergic receptor alpha-2","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Visiox Pharma","amount2":0.01,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.01,"dosageForm":"Solution","sponsorNew":"Visiox Pharma \/ Founding Partners","highestDevelopmentStatusID":"10","companyTruncated":"Visiox Pharma \/ Founding Partners"},{"orgOrder":0,"company":"Slayback Pharma","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Dr. Reddy's Laboratories Enters Into a Licensing Agreement with Slayback Pharma to Obtain Exclusive Rights in The First-To-File ANDA For the Private Label Version of Lumify\u00ae in The U.S.","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Brimonidine Tartrate","moa":"Adrenergic receptor alpha-2","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Slayback Pharma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution","sponsorNew":"Slayback Pharma \/ Dr. Reddy\u2019s Laboratories","highestDevelopmentStatusID":"10","companyTruncated":"Slayback Pharma \/ Dr. Reddy\u2019s Laboratories"},{"orgOrder":0,"company":"LENZ Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LENZ Therapeutics Announces Positive Topline Data from Phase 2 INSIGHT Trial of LNZ100 and LNZ101 to Treat Presbyopia","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Brimonidine Tartrate","moa":"ACh receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"LENZ Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"LENZ Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"LENZ Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Visiox Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Visiox Pharma Announces FDA Acceptance of New Drug Application for Glaucoma","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Brimonidine Tartrate","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Visiox Pharma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution","sponsorNew":"Visiox Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Visiox Pharma \/ Not Applicable"},{"orgOrder":0,"company":"LENZ Therapeutics","sponsor":"Sectoral Asset Management","pharmaFlowCategory":"D","amount":"$83.5 million","upfrontCash":"Undisclosed","newsHeadline":"LENZ Therapeutics Announces $83.5 Million Series B Financing to Advance its Presbyopia Treatments LNZ100 and LNZ101 and Provides Update on Ongoing Phase 3 Studies","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Series B Financing","leadProduct":"Aceclidine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"LENZ Therapeutics","amount2":0.080000000000000002,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"Solution","sponsorNew":"LENZ Therapeutics \/ Sectoral Asset Management","highestDevelopmentStatusID":"10","companyTruncated":"LENZ Therapeutics \/ Sectoral Asset Management"},{"orgOrder":0,"company":"Visus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Visus Therapeutics Completes Enrollment in BRIO-I, a Phase 3 Clinical Trial of BRIMOCHOL\u2122 PF for the Treatment of Presbyopia","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Carbachol","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Visus Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Visus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Visus Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Visus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Visus Therapeutics Announces Positive Topline Clinical Data from Phase 3 Pivotal BRIO-I Trial of BRIMOCHOL PF\u2122 for the Treatment of Presbyopia","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Carbachol","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Visus Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Visus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Visus Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Nod for Alembic\u2019S Generic Ophthalmic Solution","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Brimonidine Tartrate","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Alembic Pharmaceuticals Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alembic Pharmaceuticals Limited \/ Not Applicable"},{"orgOrder":0,"company":"Graphite Bio","sponsor":"LENZ Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"LENZ Therapeutics and Graphite Bio Announce Merger Agreement","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Merger","leadProduct":"Aceclidine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Graphite Bio","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Graphite Bio \/ LENZ Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Graphite Bio \/ LENZ Therapeutics"},{"orgOrder":0,"company":"Graphite Bio","sponsor":"Versant Ventures","pharmaFlowCategory":"D","amount":"$53.5 million","upfrontCash":"Undisclosed","newsHeadline":"LENZ Therapeutics and Graphite Bio Announce Merger Agreement","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Private Placement","leadProduct":"Aceclidine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Graphite Bio","amount2":0.050000000000000003,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"Solution","sponsorNew":"Graphite Bio \/ Versant Ventures","highestDevelopmentStatusID":"10","companyTruncated":"Graphite Bio \/ Versant Ventures"},{"orgOrder":0,"company":"Graphite Bio","sponsor":"Versant Ventures","pharmaFlowCategory":"D","amount":"$53.5 million","upfrontCash":"Undisclosed","newsHeadline":"LENZ Completes Merger with Graphite Bio and Updates On Progress","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Private Placement","leadProduct":"Aceclidine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Graphite Bio","amount2":0.050000000000000003,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"Solution","sponsorNew":"Graphite Bio \/ Versant Ventures","highestDevelopmentStatusID":"10","companyTruncated":"Graphite Bio \/ Versant Ventures"},{"orgOrder":0,"company":"LENZ Therapeutics","sponsor":"Graphite Bio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"LENZ Completes Merger with Graphite Bio and Provides Clinical and Corporate Update","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Merger","leadProduct":"Aceclidine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"LENZ Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"LENZ Therapeutics \/ Graphite Bio","highestDevelopmentStatusID":"10","companyTruncated":"LENZ Therapeutics \/ Graphite Bio"},{"orgOrder":0,"company":"LENZ Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LENZ Therapeutics Announces Positive Topline Data from Phase 3 CLARITY Presbyopia Trials","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Aceclidine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"LENZ Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"LENZ Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"LENZ Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lupin receives U.S. FDA approval for Brimonidine Tartrate Ophthalmic Solution","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Brimonidine Tartrate","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"","graph3":"Lupin Ltd","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"","highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Lupin Ltd \/ Not Applicable","highestDevelopmentStatusID":"13","companyTruncated":"Lupin Ltd \/ Not Applicable"}]
Find Clinical Drug Pipeline Developments & Deals for Brimonidine Tartrate
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target